HCMHutchmedRunning, no new patients
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 412 (planned)
- Started
- Sep 6, 2021
- Main results expected
- May 30, 2028
- Fully finished
- May 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS
Measured over: 17 months after the last patient enrolled
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05009836 · record last updated 2026-09-22 · checked 2026-11-09 15:42 UTC